CB 1158

Drug Profile

CB 1158

Alternative Names: CB-1158; INCB 01158

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Calithera Biosciences; Mars Symbioscience
  • Developer Calithera Biosciences
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Arginase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 22 Mar 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in USA (PO) before March 2017 (Incyte corporation form 10-k, March 2017)
  • 30 Jan 2017 CB 1158 licensed to Incyte Corporation worldwide
  • 29 Nov 2016 Pharmacodynamics data from a preclinical study presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top